ADAMA Ltd. (SHE:000553)
China
· Delayed Price · Currency is CNY | Market Cap | 13.90B |
| Revenue (ttm) | 28.94B |
| Net Income (ttm) | -1.05B |
| Shares Out | 2.33B |
| EPS (ttm) | -0.45 |
| PE Ratio | n/a |
| Forward PE | 23.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,167,200 |
| Average Volume | 10,712,375 |
| Open | 6.08 |
| Previous Close | 6.23 |
| Day's Range | 6.06 - 6.21 |
| 52-Week Range | 5.42 - 7.70 |
| Beta | 0.36 |
| RSI | 49.08 |
| Earnings Date | Apr 30, 2026 |
About ADAMA
ADAMA Ltd., together with its subsidiaries, develops, manufactures, and commercializes crop protection products in Israel and internationally. The company operates through Crop Protection (Agro), and Intermediates and Ingredients segments. It provides herbicides, fungicides, and insecticides to protect agricultural crops from weeds, diseases, and insects; and other crop-protection products, such as miticides and nematicides, and intermediates to produce active ingredients for crop protection, as well as seed treatment products. The company also... [Read more]
Financial Performance
In 2025, ADAMA's revenue was 28.94 billion, a decrease of -1.84% compared to the previous year's 29.49 billion. Losses were -1.05 billion, -63.98% less than in 2024.
Financial StatementsNews
ADAMA Earnings Call Transcript: Q4 2025
2025 saw a 2% sales decline but a 25% EBITDA increase, driven by cost optimization and operational efficiencies. Despite a missile strike at a key facility, profitability and cash flow improved, with positive adjusted net profit and strong free cash flow of $231 million.
ADAMA Earnings Call Transcript: Q2 2025
Q2 and H1 2025 saw strong EBITDA and margin growth, with the first top-line increase since 2022, driven by volume rebound and cost efficiencies. Despite ongoing price pressure and regional challenges, the transformation plan is delivering results and supporting future growth.
ADAMA Earnings Call Transcript: Q4 2024
Despite an 11% sales decline in 2024, EBITDA grew 15% and gross margin improved to 25.6%, driven by cost control, product mix, and the Fight Forward transformation. Free cash flow and inventory management were strong, with further benefits expected as structural changes continue.
ADAMA Earnings Call Transcript: Q3 2024
EBITDA and cash flow improved significantly year-over-year despite a 10% sales decline, driven by strict cost control, inventory optimization, and a strategic focus on higher-margin products. Persistent market price pressure and Chinese overcapacity are expected to continue into 2025.
ADAMA Earnings Call Transcript: Q2 2024
Sales declined 15% year-over-year in H1 2024, but gross margin and EBITDA improved due to a focus on higher-margin products and strict cost control. Net loss widened, yet cash flow turned positive through inventory and working capital management. Market recovery remains uncertain, with ongoing price pressure from Chinese overcapacity.